Daniella Beckman has served on our board of directors since October 2024. Ms. Beckman served as the Chief Financial Officer of Tango Therapeutics, Inc., a publicly traded biotechnology company, from September 2019 until April 2026, and as interim Chief Financial Officer from October 2016 to September 2019. From November 2015 to September 2019, she provided consulting and interim chief financial officer services for early-stage biotechnology companies. From June 2011 until August 2014, Ms. Beckman served as Chief Financial Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, where she previously served as Corporate Controller from March 2008 until June 2011. Ms. Beckman has served on the board of directors of Vor Biopharma Inc., a cell therapies company, since July 2020, and previously served on the boards of directors of Blueprint Medicines Corporation, a global precision therapy company, from December 2021 to July 2025, 5:01 Acquisition Corp., a special purpose acquisition company, from October 2020 to October 2022 and Translate Bio from October 2017 to September 2021. Ms. Beckman holds a B.S. from Boston University. We believe Ms. Beckman is qualified to serve as a member of our board of directors because of her financial expertise and leadership experience in the biopharmaceutical industry.